Nurexone Biologic Inc
(NRX.VN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,385 | 3,255 | 541 | 1,143 | 880 |
| Receivables | 358 | 390 | 98 | 82 | 135 |
| Other current assets | 41 | 32 | 1,229 | 54 | 54 |
| TOTAL | $2,784 | $3,677 | $1,982 | $1,279 | $1,069 |
| Non-Current Assets | |||||
| PPE Net | 508 | 465 | 188 | 132 | 142 |
| TOTAL | $508 | $465 | $188 | $132 | $142 |
| Total Assets | $3,292 | $4,142 | $2,170 | $1,411 | $1,211 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 306 | N/A |
| Accrued Expenses | 173 | 231 | 548 | 269 | 284 |
| Other current liabilities | N/A | N/A | 1,197 | N/A | N/A |
| TOTAL | $546 | $362 | $1,908 | $623 | $437 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2 | 29 | 95 | N/A | N/A |
| Other Non-Current Liabilities | 64 | 78 | 71 | 64 | 75 |
| TOTAL | $171 | $149 | $73 | $67 | $84 |
| Total Liabilities | $717 | $511 | $1,981 | $690 | $521 |
| Shareholders' Equity | |||||
| Retained earnings | -16,304 | -14,979 | -14,057 | -13,320 | -12,163 |
| Other shareholders' equity | 2,051 | 2,113 | 2,084 | 1,885 | 1,575 |
| TOTAL | $2,575 | $3,631 | $189 | $721 | $690 |
| Total Liabilities And Equity | $3,292 | $4,142 | $2,170 | $1,411 | $1,211 |